38 Results

People

  1. Baselga
    Baselga
  2. Drullinsky
    Drullinsky
  3. Jhaveri
    Jhaveri
  4. De Stanchina
    De Stanchina
  5. Farooki
    Farooki
  6. Razavi
    Razavi
  7. Shoushtari
    Shoushtari
  8. Solit
    Solit
  9. Berger
    Berger
  10. Chakravarty
    Chakravarty

Groups

  1. Department of Medicine (30)
  2. Solid Tumor Oncology Division (25)
  3. Breast Medicine Service (13)
  4. Sloan Kettering Institute Postdocs (9)
  5. Department of Pathology and Laboratory Medicine (8)
  6. GSK Faculty (8)
  7. Genitourinary Oncology Service (8)
  8. Survivorship Research (8)
  9. Division of Subspecialty Medicine (7)
  10. Hematologic Malignancies, Division of (6)
  1. "alpelisib"
Formats
  1. Journal Article (32)
  2. Review (6)
Groups
  1. Department of Medicine (30)
  2. Solid Tumor Oncology Division (25)
  3. Breast Medicine Service (13)
  4. Sloan Kettering Institute Postdocs (9)
  5. Department of Pathology and Laboratory Medicine (8)
  6. GSK Faculty (8)

More Groups

People
  1. Jose Baselga (4)
  2. Komal Jhaveri (4)
  3. Pamela Drullinsky (4)
  4. Alexander Shoushtari (3)
  5. Azeez Farooki (3)
  6. David Solit (3)

More People

Years
  1. 2025 (2)
  2. 2024 (8)
  3. 2023 (6)
  4. 2022 (4)
  5. 2021 (5)
  6. 2020 (4)

More Years

Publications
  1. Breast Cancer Research and Treatment (3)
  2. Breast (2)
  3. Cancer Discovery (2)
  4. Cancer Research (2)
  5. Cancer Treatment and Research (2)
  6. Integrative Cancer Therapies (2)

More Publications

Publishers
  1. Elsevier Inc. (8)
  2. Springer (6)
  3. American Association for Cancer Research (4)
  4. Cell Press (2)
  5. Elsevier Science, Inc. (2)
  6. Nature Publishing Group (2)

More Publishers

Results (38)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase Ib study of sotrastaurin, a PKC inhibitor, and alpelisib, a PI3Kα inhibitor, in patients with metastatic uveal melanoma
    Journal Article

    Shoushtari, A. N.; Khan, S.; Komatsubara, K.; Feun, L.; Acquavella, N.; Singh-Kandah, S.; Negri, T.; Nesson, A.; Abbate, K.; Cremers, S.; more...
    Cancers (2021)

    Fulltext@MSK | Save
  • Cell line-specific network models of ER(+) breast cancer identify potential PI3Kα inhibitor resistance mechanisms and drug combinations
    Journal Article

    Zañudo, J. G. T.; Mao, P.; Alcon, C.; Kowalski, K.; Johnson, G. N.; Xu, G.; Baselga, J.; Scaltriti, M.; Letai, A.; Montero, J.; more...
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Treating alpelisib-Induced hyperglycemia with very low carbohydrate diets and sodium-glucose co-transporter 2 inhibitors: A case series
    Journal Article

    Blow, T.; Hyde, P. N.; Falcone, J. N.; Neinstein, A.; Vasan, N.; Chitkara, R.; Hurd, M. A.; Sardesai, S.; Lustberg, M. B.; Flory, J. H.; more...
    Integrative Cancer Therapies (2021)

    Fulltext@MSK | Save
  • Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study
    Journal Article

    Curigliano, G.; Martin, M.; Jhaveri, K.; Beck, J. T.; Tortora, G.; Fazio, N.; Maur, M.; Hubner, R. A.; Lahner, H.; Donnet, V.; more...
    European Journal of Cancer (2021)

    Fulltext@MSK | Save
  • RETRACTED: Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): One cohort of a phase 2, multicentre, open-label, non-comparative study
    Journal Article

    Rugo, H. S.; Lerebours, F.; Ciruelos, E.; Drullinsky, P.; Ruiz-Borrego, M.; Neven, P.; Park, Y. H.; Prat, A.; Bachelot, T.; Juric, D.; more...
    Lancet Oncology (2021)

    Fulltext@MSK | Save
  • Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer
    Journal Article

    Wang, D. G.; Barrios, D. M.; Blinder, V. S.; Bromberg, J. F.; Drullinsky, P. R.; Funt, S. A.; Jhaveri, K. L.; Lake, D. E.; Lyons, T.; Modi, S.; more...
    Breast Cancer Research and Treatment (2020)

    Fulltext@MSK | Save
  • Mechanistic basis for PI3K inhibitor antitumor activity and adverse reactions in advanced breast cancer
    Review

    Drullinsky, P. R.; Hurvitz, S. A.
    Breast Cancer Research and Treatment (2020)

    Fulltext@MSK | Save
  • A phase 1b study of cetuximab and BYL719 (alpelisib) concurrent with intensity modulated radiation therapy in stage III-IVB head and neck squamous cell carcinoma
    Journal Article

    Dunn, L. A.; Riaz, N.; Fury, M. G.; McBride, S. M.; Michel, L.; Lee, N. Y.; Sherman, E. J.; Baxi, S. S.; Haque, S. S.; Katabi, N.; more...
    International Journal of Radiation Oncology, Biology, Physics (2020)

    Fulltext@MSK | Save
  • Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
    Journal Article

    Xue, J. Y.; Zhao, Y.; Aronowitz, J.; Mai, T. T.; Vides, A.; Qeriqi, B.; Kim, D.; Li, C.; de Stanchina, E.; Mazutis, L.; more...
    Nature (2020)

    Fulltext@MSK | Save
  • Combined PIK3CA and FGFR inhibition with alpelisib and infigratinib in patients with PIK3CA-mutant solid tumors, with or without FGFR alterations
    Journal Article

    Hyman, D. M.; Tran, B.; Paz-Ares, L.; Machiels, J. P.; Schellens, J. H.; Bedard, P. L.; Campone, M.; Cassier, P. A.; Sarantopoulos, J.; Vaishampayan, U.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save